Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AZ To Buy Ardea | Contract Pharma

What are you searching for?

Sign in
Breaking News

AZ To Buy Ardea

Gout candidate leads $1.3 billion buyout

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AstraZeneca will acquire Ardea Biosciences for approximately $1.26 billion. Ardea is focused on small-molecule therapeutics; its most advanced product candidate, lesinurad, is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.

Lesinurad is a selective inhibitor of URAT1, a transporter in the proximal tubule cells of the kidney that regulates uric acid excretion from the body, which is being developed as an oral, once-daily treatment for the chronic management of hyperuricaemia in patients with gout. NDA and MAA filings are planned for 1H14. AZ plans to develop and commercialize lesinurad in China and Japan. The acquisition will also give AZ access to RDEA3170, a next-generation selective URAT1 inhibitor currently in Phase I development.

“This attractive Phase III program is an excellent opportunity to leverage AstraZeneca’s global specialty and primary care sales and marketing capabilities,” said David Brennan, chief executive officer of AstraZeneca. “The Ardea team has done a great job developing lesinurad along with a promising next-generation gout program. These compounds have real potential to benefit patients.”

The boards of both companies have unanimously approved the terms of the agreement. Subject to shareholder approval from Aread and other regulatory approvals, the transaction will close in the 2Q or 3Q12.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics